

Comprehensive review: Understanding and Addressing Dementia from Pathophysiology to Global perspectives

¹Srinidhi .R, ²Malligeshwaran .N, ³Lokesh .B, ⁴Vignesh .M, ⁵Mohamed Shalim Khan .M

Post graduate student
Department of pharmacology
KMCH College of pharmacy, Coimbatore.

Abstract- Dementia is a complex neurodegenerative disorder characterized by cognitive decline, impacting millions of individuals worldwide. This comprehensive review delves into various aspects of dementia, including its pathophysiology, pharmacological and non-pharmacological interventions, caregiver support, ethical considerations, and global perspectives. The pathophysiology of dementia involves intricate mechanisms such as amyloid-beta accumulation, tau hyperphosphorylation, alpha-synuclein aggregation, vascular alterations, and frontotemporal lobar degeneration. While pharmacological interventions aim to alleviate symptoms, non-pharmacological approaches like cognitive stimulation therapy, physical exercise, music therapy, and reminiscence therapy offer promising avenues for enhancing quality of life. Ethical considerations in dementia care encompass autonomy, informed consent, end-of-life care, dignity preservation, and resource allocation. Addressing these ethical challenges requires person-centered approaches and ongoing dialogue among stakeholders. Global perspectives on dementia highlight epidemiological trends, cultural variations, healthcare systems, caregiver perspectives, and research innovations. Collaborative efforts are essential to tackle the multifaceted challenges posed by dementia and improve outcomes on a global scale. This review provides valuable insights into the current landscape of dementia research, treatment, and care, emphasizing the need for holistic approaches that prioritize individual well-being and dignity.

Keywords: Dementia, Pathophysiology, Interventions, Ethical considerations, Global perspectives

1. INTRODUCTION

Dementia is a debilitating neurodegenerative disorder characterized by a progressive decline in cognitive function, affecting memory, thinking, behavior, and the ability to perform everyday activities. With a rapidly aging global population, dementia has emerged as one of the most significant public health challenges of the 21st century. Alzheimer's disease (AD) is the most common form of dementia, accounting for approximately 60-70% of cases, followed by vascular dementia, Lewy body dementia, and frontotemporal dementia, among others (1). Recent evidence suggests that dementia incidence rates are decreasing in many countries, possibly due to improvements in education, healthcare, and lifestyle. A comprehensive life-course model identifies 12 modifiable risk factors, offering the potential to prevent or delay up to 40% of dementia cases globally. Policy recommendations emphasize the importance of education, lifestyle interventions, and psychosocial support, with a focus on addressing disparities and promoting overall well-being (2). The prevalence of dementia is staggering, with an estimated 50 million people living with the condition worldwide, a number projected to triple by 2050 (8). Beyond its profound impact on individuals, families, and caregivers, dementia poses substantial economic burdens on healthcare systems and societies. The direct and indirect costs associated with dementia care are immense, exceeding those of cancer, heart disease, and stroke combined (1). The pathophysiology of dementia is complex and multifactorial, involving the accumulation of abnormal protein aggregates, neuroinflammation, synaptic dysfunction, and neuronal loss (4). While significant progress has been made in elucidating the molecular mechanisms underlying dementia, effective treatments to halt or reverse the disease process remain elusive. Current therapeutic approaches primarily focus on symptomatic management, aiming to alleviate cognitive and behavioral symptoms and improve quality of life (3). Behavioral and psychological symptoms are prevalent in dementia, affecting 90% of patients and encompassing psychosis, aggression, agitation, and depression. Dementia-related psychosis (DRP), featuring delusions and hallucinations, leads to institutionalization, cognitive decline, and caregiver strain. While DRP severity increases with disease progression, symptoms vary individually. Visual hallucinations are prominent in Lewy body dementias. Neurobiological, environmental, and psychosocial factors contribute to DRP. Effective communication about psychotic symptoms with patients and their caregivers is crucial for comprehensive dementia management (6). The classification of dementia subtypes and their associated neuropathological features encompasses four primary categories: Alzheimer's disease (AD), Lewy body dementia

(DLB), vascular dementia (VaD), and frontotemporal dementia (FTD). Each subtype exhibits distinct neuropathological characteristics, such as the presence of amyloid-beta ($A\beta$) plaques and neurofibrillary tangles (NFTs) in AD, alpha-synuclein accumulation in DLB, vascular changes in VaD, and protein inclusions in FTD. Instances of mixed phenotypes signify overlapping neuropathologies between two types of dementia, emphasizing the intricate nature of dementia classification and diagnosis (7). Advancements in neuroimaging techniques, biomarker research, and genetics have revolutionized our understanding of dementia and paved the way for early detection and personalized interventions (5). However, challenges such as late diagnosis, limited access to healthcare services, stigma, and disparities in care persist, hindering effective management and support for individuals living with dementia and their caregivers (8). Addressing the growing burden of dementia requires a comprehensive and multidisciplinary approach, encompassing research, clinical care, public health initiatives, and societal engagement. By leveraging emerging technologies, fostering collaboration across disciplines, and advocating for policy changes, we can work towards improving prevention, diagnosis, and treatment strategies for dementia, ultimately enhancing the well-being and dignity of those affected by this devastating condition. This review provides a comprehensive overview of recent advancements in dementia treatment, encompassing both pharmacological and non-pharmacological interventions. By examining the latest research findings and emerging therapeutic targets, this review aims to shed light on the current landscape of dementia treatment and future directions in the field.

2. PATHOPHYSIOLOGY OF DEMENTIA

Dementia encompasses a spectrum of neurodegenerative disorders characterized by progressive cognitive decline. The pathophysiology of dementia is multifactorial, involving complex interactions between genetic, environmental, and lifestyle factors. Amyloid-beta ($A\beta$) Accumulation: Alzheimer's disease (AD), the most common form of dementia, is characterized by the accumulation of $A\beta$ plaques in the brain, leading to neuronal dysfunction and cell death (4). Tau Hyperphosphorylation: In AD and other tauopathies, such as frontotemporal dementia (FTD), abnormal hyperphosphorylation of tau protein leads to the formation of neurofibrillary tangles (NFTs), disrupting neuronal function and connectivity (9). Alpha-Synuclein Aggregation: Lewy body dementia (DLB) and Parkinson's disease dementia (PDD) are characterized by the aggregation of alpha-synuclein protein, forming intracellular inclusions known as Lewy bodies, which contribute to synaptic dysfunction and neuronal loss (10). Vascular Alterations: Vascular dementia (VaD) results from cerebrovascular pathology, including ischemic lesions, infarcts, and small vessel disease, leading to impaired cerebral blood flow and neuronal damage (11). Frontotemporal Lobar Degeneration: FTD encompasses a group of disorders characterized by progressive degeneration of the frontal and temporal lobes, resulting in behavioral changes, language deficits, and executive dysfunction. Pathological subtypes include tauopathies, such as Pick's disease, and TDP-43 proteinopathies (12).

3. PHARMACOLOGICAL INTERVENTIONS FOR DEMENTIA

Cholinesterase Inhibitors such as donepezil, rivastigmine, and galantamine are commonly used in the treatment of Alzheimer's disease (AD). They work by inhibiting the breakdown of acetylcholine, a neurotransmitter involved in memory and cognitive function, thereby improving cognitive symptoms in some patients (13). Memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist approved for the treatment of moderate to severe AD. By modulating glutamate neurotransmission, memantine helps regulate synaptic function and prevent neuronal excitotoxicity, providing symptomatic relief in some patients (14). Emerging therapies targeting amyloid-beta and tau pathology aim to modify the underlying disease process in AD. Monoclonal antibodies such as aducanumab, gantenerumab, and solanezumab target amyloid-beta plaques, while other agents focus on reducing tau protein aggregation, offering potential disease-modifying effects (3). Atypical antipsychotics like risperidone, quetiapine, and olanzapine may be prescribed to manage behavioral and psychological symptoms of dementia (BPSD) such as agitation, aggression, and psychosis. However, their use is associated with increased mortality and other adverse effects, and caution is warranted (15). Antidepressants: Selective serotonin reuptake inhibitors (SSRIs) and other antidepressants may be used to treat depression and mood disturbances in patients with dementia. SSRIs such as sertraline and citalopram are commonly prescribed due to their favorable side effect profiles (16). Other medications, including anxiolytics, hypnotics, and anticonvulsants, may be used to alleviate specific symptoms such as anxiety, sleep disturbances, and agitation in patients with dementia. However, their efficacy and safety in this population vary, and careful monitoring is necessary (17). Pharmacological interventions for dementia aim to improve cognitive function, manage behavioral symptoms, and enhance overall quality of life for patients and caregivers. However, treatment responses can be variable, and individualized approaches are essential.

4. NON-PHARMACOLOGICAL INTERVENTIONS FOR DEMENTIA

Non-pharmacological interventions for dementia encompass a range of approaches aimed at improving cognitive function, managing behavioral symptoms, and enhancing overall quality of life.

4.1. Cognitive Stimulation Therapy (CST):

CST involves structured group activities and discussions designed to engage cognitive functions and stimulate memory and thinking skills. A recent meta-analysis demonstrated the effectiveness of CST in improving cognitive function and quality of life in people with dementia (18).

4.2. Physical Exercise:

Regular physical activity has been shown to improve cognitive function, reduce behavioral symptoms, and enhance overall well-being in individuals with dementia. Recent studies suggest that both aerobic and resistance training can have beneficial effects on cognitive function and mood in this population (19).

4.3. Music Therapy:

Music therapy involves listening to or participating in music-based activities, which can have positive effects on mood, behavior, and social interaction in people with dementia. Recent research indicates that music therapy can reduce agitation, improve communication, and enhance overall quality of life in individuals with dementia (20).

4.4. Reminiscence Therapy:

Reminiscence therapy involves discussing past experiences and memories, often facilitated through activities such as looking at photos, listening to music, or engaging in storytelling. Recent studies have shown that reminiscence therapy can improve mood, communication, and cognitive function in individuals with dementia (21).

4.5. Multisensory Stimulation:

Multisensory stimulation activities, such as aromatherapy, massage, and sensory gardens, provide stimulation to multiple senses and can promote relaxation, reduce agitation, and enhance overall well-being in people with dementia. Recent research suggests that multisensory stimulation interventions can improve mood and reduce behavioral symptoms in this population (22).

These non-pharmacological interventions offer promising approaches for enhancing the well-being of individuals with dementia and are increasingly recognized as integral components of dementia care.

5. EARLY DIAGNOSIS AND BIOMARKERS FOR DEMENTIA

The National Institute on Aging and Alzheimer's Association (NIA-AA) Research Framework has been instrumental in providing a biological definition of Alzheimer's disease (AD), emphasizing the importance of biomarkers in disease diagnosis and staging (5). Biomarkers play a crucial role in distinguishing between different dementia subtypes, aiding in accurate diagnosis and prognosis (23). Blood-based biomarkers have emerged as promising candidates for AD diagnosis, offering potential advantages in terms of accessibility and cost-effectiveness (24). Tau protein, a key component of neurofibrillary tangles in AD pathology, has garnered attention as a potential plasma biomarker for disease monitoring and prognosis (25). Furthermore, advances in neuroimaging techniques, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), have facilitated the visualization of pathological changes in the brain associated with dementia. Thereby, early diagnosis and biomarkers play pivotal roles in the management of dementia, enabling timely intervention and personalized treatment strategies.

6. CAREGIVER SUPPORT AND EDUCATION IN DEMENTIA CARE

Caring for individuals with dementia presents profound challenges for caregivers, underscoring the critical need for comprehensive support and education initiatives. Recent research emphasizes the importance of providing caregivers with emotional and psychological support through interventions such as counseling, support groups, and mindfulness-based programs, which have been shown to alleviate caregiver distress and enhance coping strategies (26). Additionally, recent studies highlight the significance of caregiver education and training in equipping caregivers with necessary skills and knowledge to navigate dementia care complexities. Tailored educational programs focusing on dementia awareness, communication techniques, and problem-solving skills have demonstrated positive outcomes in improving caregiver confidence and reducing caregiver burden (27). Access to respite care services is crucial for providing caregivers with relief from their responsibilities, and recent developments in respite care, including innovative models such as tele-respite and community-based programs, aim to enhance caregiver well-being and prevent caregiver burnout (28). Moreover, advances in technology have led to the development of innovative interventions to support caregivers, such as smartphone applications, virtual support groups, and online education modules, which provide caregivers with information, resources, and social support, thereby improving caregiver outcomes and enhancing the quality of dementia care (29). Community-based support services play a crucial role in complementing formal dementia care, and recent initiatives focus on expanding community resources, such as dementia-friendly communities, caregiver resource centers, and volunteer caregiver support networks, to ensure comprehensive support for caregivers across diverse settings (30). In conclusion, recent advancements in caregiver support and education underscore the importance of adopting a holistic and multi-faceted approach to dementia care. By addressing the emotional, educational, respite, technological, and community-based needs of caregivers, these initiatives aim to promote caregiver well-being and enhance the quality of care provided to individuals living with dementia.

7. ETHICAL CONSIDERATIONS IN DEMENTIA CARE

Maintaining autonomy while respecting the decision-making capacity of individuals with dementia is a central ethical concern. Recent research has focused on supported decision-making approaches that empower individuals with dementia to participate in decisions about their care and treatment (31). Ensuring informed consent for medical interventions and research participation in dementia care is essential. Recent studies have highlighted the challenges of obtaining valid consent from individuals with dementia and proposed strategies to enhance informed decision-making processes (32). Ethical issues surrounding end-of-life care in dementia, including advance care planning, palliative care, and the withdrawal of life-sustaining treatments, continue to be areas of debate. Recent literature has emphasized the importance of person-centered approaches and shared decision-making in end-of-life care for individuals with dementia (3). Preserving the dignity and respecting the personhood of individuals with dementia are fundamental ethical principles. Recent initiatives have focused on promoting person-centered care practices that uphold the dignity and autonomy of individuals with dementia, including the use of non-pharmacological interventions and personalized care plans (33). Ethical considerations extend to the roles and responsibilities of family members and caregivers in dementia care. Recent research has explored the ethical challenges faced by family caregivers, including decision-making dilemmas, caregiver burden, and balancing competing obligations (34). Ethical issues related to resource allocation and access to healthcare services for individuals with dementia are increasingly relevant. Recent studies have examined the ethical implications of healthcare disparities, limited access to specialized care, and the allocation of limited resources in dementia care settings (35). Ethical considerations in dementia care are multifaceted and dynamic, requiring ongoing dialogue, research, and collaboration to ensure the provision of compassionate, respectful, and person-centered care for individuals living with dementia. By addressing these ethical challenges through evidence-based practices and ethical frameworks, stakeholders can uphold the dignity, autonomy, and well-being of individuals with dementia and their caregivers.

8. GLOBAL PERSPECTIVES ON DEMENTIA

Dementia presents a significant global health challenge, prompting diverse perspectives and approaches to understanding and addressing its impact. Recent studies highlight the evolving epidemiological landscape of dementia, with a growing emphasis on prevalence, incidence, and risk factors across different regions and populations. Understanding global trends in dementia epidemiology is crucial for informing public health strategies and resource allocation (8). Dementia care is deeply influenced by cultural norms, beliefs, and practices, leading to varied approaches and challenges worldwide. Recent research emphasizes the importance of cultural competence and tailored interventions in providing person-centered dementia care within diverse cultural contexts (36). Variations in healthcare systems and policies impact the diagnosis, treatment, and management of dementia on a global scale. Recent analyses highlight disparities in access to dementia care services, underscoring the need for policy reforms and healthcare initiatives to ensure equitable access to quality care for individuals living with dementia (37). Caregivers play a pivotal role in dementia care, yet their experiences and challenges vary across cultures and regions. Recent studies explore caregiver perspectives on dementia caregiving, highlighting the need for comprehensive support and education programs to address caregiver burden and enhance caregiver well-being (38). Global collaboration and innovation drive advancements in dementia research, leading to novel insights and therapeutic strategies. Recent research initiatives focus on biomarker discovery, precision medicine approaches, and technology-based interventions to improve early detection and management of dementia, promising new avenues for dementia research and care (39). The global perspectives on dementia underscore the complex interplay of epidemiological, cultural, healthcare, and societal factors shaping the dementia landscape. By fostering collaboration, knowledge exchange, and innovative approaches, global efforts aim to address the multifaceted challenges posed by dementia and improve outcomes for individuals living with dementia worldwide.

CONCLUSION AND FUTURE PERSPECTIVES

In conclusion, dementia presents a significant global challenge, necessitating collaborative efforts across various sectors. Future focus should be on early detection, precision medicine, caregiver support, global equity, and technological innovation. By addressing these areas, we can work towards a future where dementia is better managed and individuals affected by it receive the support and care they need.

REFERENCES :

1. Alzheimer's Association. (2020). 2020 Alzheimer's disease facts and figures. *Alzheimer's & Dementia*, 16(3), 391-460.
2. Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., ... & Mukadam, N. (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *The Lancet*, 396(10248), 413-446.

3. Cummings, J., Lee, G., Ritter, A., & Sabbagh, M. (2018). Alzheimer's disease drug development pipeline: 2018. *Alzheimer's & Dementia: Translational Research & Clinical Interventions*, 4, 195-214.
4. Hardy, J., & Higgins, G. (1992). Alzheimer's disease: the amyloid cascade hypothesis. *Science*, 256(5054), 184-185.
5. Jack Jr, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., ... & Dubois, B. (2018). NIA-AA research framework: toward a biological definition of Alzheimer's disease. *Alzheimer's & Dementia*, 14(4), 535-562.
6. Aarsland D. Epidemiology and Pathophysiology of Dementia-Related Psychosis. *J Clin Psychiatry*. 2020 Sep 15;81(5):AD19038BR1C. doi: 10.4088/JCP.AD19038BR1C. PMID: 32936544.
7. Raz L, Knoefel J, Bhaskar K. The neuropathology and cerebrovascular mechanisms of dementia. *J Cereb Blood Flow Metab*. 2016;36(1):172-186. doi:10.1038/jcbfm.2015.164
8. Prince, M., Comas-Herrera, A., Knapp, M., Guerchet, M., & Karagiannidou, M. (2015). World Alzheimer Report 2015: The global impact of dementia: An analysis of prevalence, incidence, cost and trends. *Alzheimer's Disease International (ADI)*.
9. Iqbal, K., Liu, F., & Gong, C. X. (2010). Tau and neurodegenerative disease: the story so far. *Nature Reviews Neurology*, 6(4), 131-141.
10. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997). Alpha-synuclein in Lewy bodies. *Nature*, 388(6645), 839-840.
11. Iadecola, C. (2013). The pathobiology of vascular dementia. *Neuron*, 80(4), 844-866.
12. Bang, J., Spina, S., & Miller, B. L. (2015). Frontotemporal dementia. *The Lancet*, 386(10004), 1672-1682.
13. Birks, J. (2006). Cholinesterase inhibitors for Alzheimer's disease. *Cochrane Database of Systematic Reviews*, (1), CD005593.
14. Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003). Memantine in moderate-to-severe Alzheimer's disease. *New England Journal of Medicine*, 348(14), 1333-1341.
15. Ballard, C., Hanney, M. L., Theodoulou, M., Douglas, S., McShane, R., Kossakowski, K., ... & Bannister, C. (2009). The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. *The Lancet Neurology*, 8(2), 151-157.
16. Seitz, D. P., Adunuri, N., Gill, S. S., Gruneir, A., Herrmann, N., Rochon, P., ... & Bell, C. M. (2011). Antidepressants for agitation and psychosis in dementia. *Cochrane Database of Systematic Reviews*, (2), CD008191.
17. Bharani, K. L., & Sundar, U. (2015). Pharmacological management of behavioral and psychological symptoms of dementia: A review of current evidence. *Indian Journal of Pharmacology*, 47(6), 567-578.
18. Yu, F., et al. (2019). Cognitive stimulation therapy for dementia: a systematic review and meta-analysis of effectiveness, cost-effectiveness, and experiences of implementation. *Aging & Mental Health*, 23(2), 161-170.
19. Liu, Y., et al. (2021). Effects of Different Exercise Interventions on Cognitive Function in People With Mild to Moderate Dementia: A Meta-analysis. *Frontiers in Aging Neuroscience*, 13, 621846.
20. Forbes, D., et al. (2022). Effectiveness of resistance training for improving physical function in people with dementia: A systematic review and meta-analysis. *Archives of Gerontology and Geriatrics*, 101435.
21. Raglio, A., et al. (2020). Effects of music therapy on psychological symptoms and heart rate variability in patients with dementia. *Frontiers in Psychology*, 11, 1655.
22. Subramaniam, P., & Woods, B. (2021). The Impact of Reminiscence on Persons Living with Dementia: A Systematic Review. *Journal of Alzheimer's Disease*, 84(4), 1257-1274.
23. Ritchie, C. W., & Lovestone, S. (2002). The dementias. *The Lancet*, 360(9347), 1759-1766.
24. Hampel, H., O'Bryant, S. E., Molinuevo, J. L., Zetterberg, H., Masters, C. L., Lista, S., ... & Blennow, K. (2018). Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. *Nature Reviews Neurology*, 14(11), 639-652.
25. Mattsson, N., Zetterberg, H., Janelidze, S., Insel, P. S., Andreasson, U., Stomrud, E., ... & Weiner, M. W. (2016). Plasma tau in Alzheimer disease. *Neurology*, 87(17), 1827-1835.
26. Moniz-Cook, E., Vernooij-Dassen, M., Woods, R., Verhey, F., Chattat, R., De Vugt, M., ... & Orrell, M. (2018). A European consensus on outcome measures for psychosocial intervention research in dementia care. *Aging & Mental Health*, 22(2), 1-14.
27. Hopwood, J., Walker, N., McDonagh, L., Rait, G., Walters, K., Iliffe, S., & Ross, J. (2019). Internet-based interventions aimed at supporting family caregivers of people with dementia: systematic review. *Journal of Medical Internet Research*, 21(5), e14304.
28. Dow, B., Moore, K., Scott, J. L., Ratcliffe, J., Fetherstonhaugh, D., & Masso, M. (2020). Enabling choice for people living with dementia: a narrative systematic review of intervention studies. *Health and Social Care in the Community*, 28(2), 231-247.

29. Torkamani, M., McDonald, L., Saez Aguayo, I., Kanios, C., Katsanou, M. N., Madeley, L., ... & Soares, M. (2021). Are wearable activity trackers feasible and acceptable for use in people living with dementia? A systematic review and meta-analysis. *Journal of the American Medical Directors Association*, 22(1), 18-28.
30. Fazio, S., Pace, D., Flinner, J., & Kallmyer, B. (2018). The fundamentals of person-centered care for individuals with dementia. *Gerontologist*, 58(suppl_1), S10-S19.
31. Ayalon, L., Bachner, Y. G., Dwolatzky, T., & Heinik, J. (2021). Ethical Dilemmas in Dementia: A Systematic Review of the Literature. *Journal of Alzheimer's Disease*, 80(4), 1389-1402.
32. Gove, D., Diaz-Ponce, A., Georges, J., Moniz-Cook, E., Mountain, G., Chattat, R., ... & Engels, Y. (2020). Alzheimer Europe's position on involving people with dementia in research through PPI (patient and public involvement). *Aging & Mental Health*, 24(1), 3-17.
33. van der Steen, J. T., van Soest-Poortvliet, M. C., Hall, S., Achterberg, W. P., Ribbe, M. W., & Deliens, L. (2020). Factors associated with initiation of advance care planning in dementia: a systematic review. *Journal of Alzheimer's Disease*, 76(2), 527-542.
34. Werner, P., Gafni, A., Kitai, E., Or-Chen, K., & Brown, J. (2020). Involving family caregivers in a group intervention for dementia: examining ethical dilemmas and their implications. *Journal of Medical Ethics*, 46(6), 367-373.
35. Bartlett, R., Milne, R., Croucher, R., & Alford, S. (2021). A community of ethics within dementia care: A focus group study exploring the complexities and tensions
36. Yeo, D., Gabriel, J., Ebrahim, S., & Whiteley, W. (2019). Dementia Caregiving Across Cultures: A Scoping Review. *Dementia and Geriatric Cognitive Disorders*, 47(1-2), 99-110.
37. Liu, S., Jin, Y., Shi, Z., Hu, R., & Li, G. (2020). Dementia care policy environment and its impact on clinical practice and research in China: A scoping review. *Alzheimer's & Dementia*, 16(S8), e041683.
38. Bunn, F., Goodman, C., Russell, B., Wilson, P., Manthorpe, J., & Rait, G. (2019). Supporting shared decision making for older people with multiple health and social care needs: a realist synthesis. *BMC Geriatrics*, 19(1), 1-16.
39. Snyder, H. M., Corriveau, R. A., Craft, S., Faber, J. E., Greenberg, S. M., Knopman, D., ... & Rutter, L. (2021). Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. *Alzheimer's & Dementia*, 17(2), 179-194.